Navigation Links
QRxPharma Announces Successful Completion Of A$7.5 Million Placement
Date:11/13/2013

products. Based on a development strategy that focuses on enhancing the clinical utility of currently approved compounds as well as bringing new products to market, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. In Q4 2013, the Company plans to refile with the US Food and Drug Administration a New Drug Application for its lead product candidate, immediate release MOXDUO®, for the treatment of acute pain. QRxPharma has entered into strategic agreements with Actavis Inc., Paladin Labs Inc. and Aspen Group for the commercialisation of immediate release MOXDUO in the US, Canada, Australia (including New Zealand and Oceania) and South Africa. The Company's clinical pipeline includes an intravenous (IV) and controlled release (CR) formulation of MOXDUO. QRxPharma is also collaborating with Aesica Formulation Development Limited, for the worldwide promotion of QRxPharma's proprietary Stealth Beadlets™ abuse deterrence technology. For more information, visit www.qrxpharma.com.

Forward Looking Statements
This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By t
'/>"/>

SOURCE QRxPharma Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Granted Additional US Patent on MoxDuo®
2. QRxPharma Granted US Patent On Hybrid Opioids
3. QRxPharma Announces Collaboration With Aesica
4. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
5. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
6. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
7. Misonix Announces New Distribution Agreement For Panama
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)...  Boston Scientific has released the primary endpoint ... Failure (NECTAR-HF) clinical trial, the first and only ... (VNS) for the treatment of heart failure patients.  ... Cardiology and Director of the Clinical Investigation Center ... de la Recherche Medicale presented the results at ...
(Date:8/30/2014)... 2014   Royal Philips  (NYSE: PHG, AEX: PHIA) ... new ultrasound system designed to enable global hospitals and ... volumes and cost pressures. Making its debut at the  ... Barcelona this week, Affiniti provides innovative ... fewer resources deliver high quality patient care. ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... The report firstly reviews the basic information of ... manufacturing technology. The report then explores global and ... their product specification, capacity, Production value, and market ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
... - Inovio Biomedical,Corporation (AMEX:INO), focused on the ... diseases and a novel alternative to,surgery to ... partner, Vical Incorporated, presented positive interim,safety and ... ongoing Phase I,clinical trial using Inovio's electroporation ...
... Clinical results from a,Phase II study presented ... Society (AHS) annual meeting showed that MK-0974, ... significantly improved migraine pain relief,two hours after ... was,sustained through 24 hours. MK-0974 was generally ...
Cached Medicine Technology:Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 2Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 3Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 4Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 5Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5
(Date:8/30/2014)... United Theological Seminary is pleased to announce ... Master of Theological Studies (MTS). , This ... for students who wish to pursue further academic study of ... serve the Church and community. Previously, students needed to be ... attend classes from any location where there is an internet ...
(Date:8/30/2014)... 30, 2014 Hands On ... which offers the complete spa experience combining elegant ... and the most important ingredient of all, states ... licensed pro's! People will enjoy the get-away feel, ... The website reads, "Step into the spacious, luxurious ...
(Date:8/30/2014)... 2014 Patients suffering from vitiligo can ... a new review published by Daily Gossip. , ... so there is no wonder that numerous sufferers search ... Vitiligo Treatment is one of the most appreciated such ... promises to stop the spread of this disorder immediately, ...
(Date:8/30/2014)... Daily Gossip reveals in its review a program created ... who shows a unique formula to get inside a man’s ... that the program goes beyond mere attraction and actually helps ... indicates that the program was created by dating expert Alex ... to make a man feel emotionally addicted. , Learn more ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Daily Gossip ... that keeps anxiety and panic attacks under control with ... Away" program review describes this new method as ... control panic attacks and overcome general anxiety related disorders. ... successful is the fact that it can be accessed ...
Breaking Medicine News(10 mins):Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:Natural Vitiligo Treatment Review Exposes Fast Method for Skin Repigmentation 2Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2
... Solutions for Medical Equipment, Building Infrastructure and Automation, ... NEW YORK, March 23 Via Christi Health ... a wide range of technology and service solutions ... Christi Health System,s strategic plan.(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ...
... Siemens Financial Services, Inc. announced today that ... to El Camino Hospital in Mountain View, California. ... a variety of Siemens Medical Solutions equipment which ... hospital under construction.(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )"For more ...
... Education Virtual Lecture for Healthcare ProfessionalsVOORHEES, N.J., March ... infection (CDI) is changing rapidly and has ... and severity. Management of CDI can be challenging ... updated. In order to effectively implement key strategies ...
... WASHINGTON, March 23 March 22 was World Water ... of the 1992 United Nations Conference on Environment and ... of World Water Day this year is Transboundary Waters: ... the Poor Act of 2005 makes access to safe ...
... MBF Healthwatch survey has revealed that a disturbing number of ... they are ,too tired, or ,can,t be bothered, having a ... 22% of parents interviewed said their children skip breakfast on ... further 20% skip breakfast on one or two school days. ...
... get relief from their symptoms and the psychological distress ... , Skin experts and psychologists at The University of ... known as ,electronic Targeted Intervention for Psoriasis, or eTIPS ... better. , "Psoriasis is a skin disease that usually ...
Cached Medicine News:Health News:Via Christi Health System and Siemens Announce Technology Alliance 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 3Health News:Clostridium difficile Infection in Primary Care: Tackling a Virulent Pathogen 2Health News:USAID World Water Day Statement 2Health News:USAID World Water Day Statement 3Health News:School kids 'wagging' breakfast are missing healthy brain fuel 2Health News:Experts turn to Web to combat distressing skin disease 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: